Cytomx Therapeutics Inc Stock Price, News & Analysis

CytomX Therapeutics (CTMX) will report its fourth quarter and full year 2021 financial results on March 1, 2022, after U.S. market close. A conference call will follow at 5:00 p.m. ET to discuss results and provide updates. CytomX focuses on oncology therapeutics, notably through its Probody® technology. Its pipeline includes investigational drugs like praluzatamab ravtansine and CX-2029, both undergoing Phase 2 studies for advanced cancer types. Interested parties can access the conference call via the company’s website.

CytomX Therapeutics (CTMX) announced on February 16, 2022, the granting of stock options to nine new employees, totaling 189,400 shares at an exercise price of $4.08. This grant was made under the 2019 Employment Inducement Incentive Plan, approved in August 2020, aimed at attracting new talent. CytomX focuses on conditionally activated oncology therapeutics, with a pipeline that includes investigational therapies for challenging cancer types, including praluzatamab ravtansine and CX-2029, which are currently in Phase 2 clinical studies.

CytomX Therapeutics (Nasdaq: CTMX) has promoted Amy C. Peterson, M.D., to president and chief operating officer, effective immediately. Dr. Peterson, previously the executive vice president and chief development officer, brings extensive experience in oncology development. CEO Sean McCarthy highlighted her contributions in advancing CytomX's Probody Therapeutic pipeline. In her new role, Dr. Peterson aims to enhance the company’s impact on cancer treatment through innovative strategies and leadership. CytomX continues to focus on developing conditionally activated biologics to improve cancer treatment outcomes.

CytomX Therapeutics (Nasdaq: CTMX) announced on January 18, 2022, the granting of stock options for 127,000 shares to four new employees at an exercise price of $3.83 per share. These options are part of the 2019 Employment Inducement Incentive Plan approved by the Company’s board in August 2020. CytomX specializes in conditionally activated therapeutics, focusing on various oncology treatments, particularly through its Probody technology platform. The company’s current clinical pipeline includes several investigational drugs aimed at treating difficult cancer types.

CytomX Therapeutics announced FDA clearance of the IND application for CX-904, its first T-cell-engaging bispecific antibody and sixth Probody candidate to enter clinical trials. Co-developed with Amgen, CX-904 is targeted at treating advanced solid tumors by selectively engaging T cells in the tumor microenvironment. The company emphasizes the innovative aspects of CX-904, which shows potent anti-tumor activity in preclinical studies and aims to initiate a Phase 1 dose-escalation study soon. CytomX aims to redefine cancer treatment with its conditionally activated therapeutics.

CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 3:00 p.m. ET. The presentation will be available live on CytomX’s website, with an archived replay accessible for 30 days post-event. CytomX is known for its innovative conditionally activated biologics aimed at enhancing cancer treatment. Their pipeline includes investigational therapies like praluzatamab ravtansine and CX-2029, currently in Phase 2 studies targeting hard-to-treat cancers.

CytomX Therapeutics (CTMX) announced preliminary Phase 2 results for CX-2029, an antibody-drug conjugate targeting advanced squamous non-small cell lung cancer (sqNSCLC) and head and neck squamous cell carcinoma (HNSCC). In sqNSCLC, the objective response rate (ORR) was 18.8%, with a disease control rate (DCR) of 87.5%. HNSCC patients showed an ORR of 4.0% and a DCR of 56.0%. No new safety signals were detected, maintaining a favorable adverse event profile. The company continues to enroll patients and is optimistic about future data releases.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in virtual fireside chats at two investor conferences in November 2021. The Jefferies Global Healthcare Conference is scheduled for November 18, with the chat available online at 3:00 a.m. ET. The Piper Sandler Virtual Healthcare Conference will follow on November 30, with the chat accessible at 10:00 a.m. ET. Archived replays will be available on the company's website for 30 days. CytomX is pioneering conditionally activated therapeutics focusing on oncology.

CytomX Therapeutics (CTMX) reported its third quarter 2021 financial results, showcasing a revenue of $18 million, consistent with 2020 figures. The company is on track to release initial data from the Phase 2 studies of CX-2029 in Q4 2021 and praluzatamab ravtansine (CX-2009) in 2022. R&D expenses increased to $29 million due to clinical trials and related costs. The company maintains a strong cash position of $336 million. Additionally, CX-904's IND filing is anticipated in late 2021, emphasizing CytomX’s commitment to advancing its conditionally activated therapeutics.